Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 26;9(6):555. doi: 10.3390/vaccines9060555

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

In vivo evaluation of the αDEC205-BZLF immunogen; (A) The viSNE maps, colored by the intensities of individual immune marker expression (CD3, CD4, CD8, and CD19); (B) FlowSOM minimal spanning tree (MST) on HuCD3+ T-cells showed both HuCD4+ T-cells and HuCD8+ T-cells; (C) Percentage of T-cell population from each vaccination group (αDEC205-Ctrl CoCx and αDEC205-BZLF) in each FlowSOM meta-cluster; (D) FlowSOM minimal spanning tree (MST) colored by the intensities of individual immune marker expression (CD8, HLA-DR, IFNγ, Tbet, CD45RO, and CD62); (E) Ex-vivo immune responsiveness to recall antigens (autologous LCLs, BZLF1 pepmix, and anti-TCR) by ELISpot; (F) Log-rank test: BZLF vaccine significantly delayed lymphoma development.